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Huntington’s Disease (HD) is characterized by a
mutation in the huntingtin (Htt) gene encoding an
expansion of glutamine repeats on the N terminus of
the Htt protein. Numerous studies have identified
Htt proteolysis as a critical pathological event in HD
postmortem human tissue and mouse HD models,
and proteases known as caspases have emerged as
attractive HD therapeutic targets. We report the
use of the substrate activity screening method
against caspase-3 and -6 to identify three novel, pan-
caspase inhibitors that block proteolysis of Htt at
caspase-3 and -6 cleavage sites. In HDmodels these
irreversible inhibitors suppressed Hdh111Q/111Q-
mediated toxicity and rescued rat striatal and cortical
neurons from cell death. In this study, the identified
nonpeptidic caspase inhibitors were used to confirm
the role of caspase-mediated Htt proteolysis in HD.
These results further implicate caspases as prom-
ising targets for HD therapeutic development.
INTRODUCTION
Huntington’s disease (HD) is a dominantly inherited neurodegen-
erative disorder characterized by progressive deterioration of
neurons in the striatum and cortex. Symptoms can occur at
any age but usually occur with an adult-onset, and patients
exhibit progressive loss of cognitive and motor function. HD is
caused by a mutation in the Htt gene with a trinucleotide (CAG)
expansion encoding glutamine repeats in the N terminus of
huntingtin (Htt), a scaffold protein with many interacting proteins
that has been shown to be involved in vesicular trafficking
(HDCRG, 1993). A neuropathological hallmark of HD in human
and mouse models is the accumulation of N-terminal Htt frag-
ments leading to cytotoxicity, suggesting that Htt proteolysis is
a critical event in pathogenesis (Davies et al., 1997; DiFigliaChemistry & Biology 17, 1189–120et al., 1997; Gafni and Ellerby, 2002; Gafni et al., 2004; Goldberg
et al., 1996; Gutekunst et al., 1999; Martindale et al., 1998).
Numerous studies have demonstrated the cleavage of Htt by
multiple proteases, including aspartyl proteases, calpains, and
caspases (Gafni and Ellerby, 2002; Gafni et al., 2004; Goldberg
et al., 1996; Lunkeset al., 2002;Wellingtonet al., 1998).Caspases
are cysteine proteases characterized by their high specificity for
substrates with an aspartic acid at the site of cleavage in the P1
position and play a prominent role in apoptosis (Pop and Salve-
sen, 2009). Dysregulation of apoptosis has been implicated in
stroke, neuronal degeneration, liver disease, cancer, and autoim-
mune disorders (Reed, 2002). Due to the dramatic neuronal cell
death in HD, it is not surprising that Htt was the first neuronal
protein identified as a caspase substrate (Goldberg et al.,
1996). A number of studies have defined the cleavage sites of
Htt for caspase-3 at amino acids 513 and 552, for caspase-2 at
amino acid 552, and for caspase-6 at amino acid 586 (Hermel
et al., 2004; Wellington et al., 1998, 2000). Recently, caspase-6
cleavage of mutant Htt and activation of caspase-6 have been
shown to play a significant role in HD pathogenesis in HDmouse
models (Hermel et al., 2004; Graham et al., 2006). Caspase-6 is
also activated in HD postmortem tissue (Hermel et al., 2004).
Although the aforementioned studies clearly implicate cas-
pase-mediated cleavage of Htt in HD, few studies have
evaluated the effects of caspase inhibition on HD cell death.
The nonspecific irreversible, peptidic fluoromethyl ketone inhib-
itor, zVAD-fmk, protected striatal neurons against malonate-
induced excitotoxicity (Schulz et al., 1998), and the reversible
caspase-3 specific inhibitor, M826, significantly displayed neu-
roprotection against malonate-induced striatal injury in a rat
model of HD (Toulmond et al., 2004). Additionally, through indi-
rect means minocycline, a tetracycline derivative with the ability
to cross the blood-brain barrier, inhibits caspase-1 and cas-
pase-3 transcriptional upregulation and delays cell death in HD
transgenic mouse models (Chen et al., 2000). The development
of small molecule, nonpeptidic inhibitors of both caspase-3 and
-6 and their evaluation in HD biology would provide useful tool
compounds to the field. Unfortunately, whereas numerous cas-
pase inhibitors have been developed (Cornelis et al., 2007;
O’Brien and Lee, 2004), most are peptidic in nature, and efficacy0, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1189
Figure 1. Screening of AMCA Substrates 1
First step in SAS method, screening diverse AMCA
substrates against caspase to yield a fluorescent AMCA
reporter group.
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and absorption, distribution, metabolism, and excretion (ADME)
properties, respectively (Talanian et al., 1997). Therefore, we
applied a substrate-based fragment approach called substrate
activity screening (SAS) to the development of nonpeptidic inhib-
itors of caspase-3 and -6. In the SAS method, which has previ-
ously been applied to proteases of the papain family (Brak
et al., 2008; Inagaki et al., 2007; Patterson et al., 2006; Wood
et al., 2005), weak binding nonpeptidic substrate fragments are
identified, optimized, and then converted to potent inhibitors.
Herein, we report the identification of three novel, nonpeptidic
pan-caspase irreversible inhibitors that blocked proteolysis of
Htt at caspase-3 and caspase-6 sites, suppressedHdh111Q/111Q-
mediated toxicity, and rescued HttN90Q73-induced degenera-
tion of rat striatal and cortical neurons.
RESULTS AND DISCUSSION
Substrate Library Synthesis and Screening
To target caspase-3, we initially set out to create a library that
incorporated the P1 aspartic acid required for caspase recogni-
tion and amide bond hydrolysis. To satisfy the goal of identifying
nonpeptidic fragments, we synthesized an initial library of 1,4-
disubstituted-1,2,3-triazole substrates 1 (Figure 1) because tria-
zoles have been demonstrated as efficient amide bond replace-
ments in the development of protease inhibitors (Brik et al., 2005;
Wood et al., 2005), and diverse functionality could readily be
introduced into the substrates using solid-phase methods (see
Supplemental Experimental Procedures available online). Sub-
strates were screened in a high-throughput fluorometric assay
to detect caspase-3-catalyzed amide bond proteolysis and
liberation of the fluorophore, 7-amino-4-methylcoumarin-3-ace-
tic acid (AMCA) (Figure 1).
Structure-Activity Relationship of AMCA Substrates
against Caspase-3
Figure 2A exhibits the relative cleavage efficiencies of a subset of
initial substrates that were evaluated. Substrate 2 with a phenyl-
ethyl group at theRposition had the lowest cleavage efficiency of
all of the substrates for which turnover was detected andwas as-
signed a relative cleavage efficiency value of 1.0. Substrates for
which no turnover was detected were given a relative cleavage
efficiency value of zero. Substrates 8 and 9 with a-branching at
the R position as provided by the cyclohexyl moiety along with
hydroxyl and amide groups, respectively, that are both capable
of H bonding, showed the highest activity. Substrate 9 was
particularly appealing because the amine functionality provides
the opportunity to introduce a variety of additional functionality
through amine acylation and reductive amination chemistry.
To further explore the effect of a-branched substituents within
the amide framework present in substrate 9, an additional collec-1190 Chemistry & Biology 17, 1189–1200, November 24, 2010 ª2010tion of substrates was prepared and evaluated (Figure 2B).When
the cyclohexyl group that introduces a,a-dibranching in sub-
strate 9 was replaced by the a-monobranched structures in
substrates 10–13, no substrate turnover was observed, which
suggests the importance of maintaining dibranched functionality
at this position. Similarly, dibranched substituents with the
smallermethyl, ethyl, and isopropyl groups all displayed reduced
cleavage efficiency (substrates 14–17). In contrast, substrate 18,
which incorporated methyl and cyclohexyl substituents with
an (S)-configuration, showed a greater than 5-fold increase
in cleavage efficiency relative to the initial cyclohexyl amide
substrate 9. It is noteworthy that caspase-3 showed very strong
chiral recognition with no cleavage observed for substrate 19,
which is the (R)-epimer of substrate 18. The strong preference
for the (S)-epimer suggests the importance of this configuration
for proper orientation and enhanced binding in the S2 pocket of
caspase-3.
With substrate 18 incorporating cyclohexyl andmethyl substit-
uents with (S)-configuration providing the highest cleavage
efficiency, we next chose to evaluate the replacement of the
acetamide group with a variety of different amides and amines
to identify key binding interactions for this region of the substrate
(representative structures shown in Figure 2C). Replacing the
acetamide in substrate 18 with the N,N-diethyl moiety in sub-
strate 20 almost completely eliminated substrate turnover,
suggesting the importance of the H-bond donor or accepting
capability of the amide functionality. In contrast, replacing the
acetamide in substrate 18 with the benzamide in substrate 21
resulted in only a modest reduction in cleavage efficiency,
demonstrating that groups considerably larger than acetamide
can be accommodated in the enzyme active site. The isosteric
secondary amine in substrate 22 resulted in a >10-fold reduction
in cleavage efficiency of the substrate, again confirming the
importance of the amide functionality either for orientation
or for hydrogen-bonding interactions. The phenyl acetamide
present in substrate 23 resulted in a modest increase in cleav-
age efficiency, whereas the isosteric phenylmethylsulfonamide
present in 24, which maintains hydrogen-bond donor and ac-
cepting capability, provided a considerable boost in cleavage
efficiency. Finally, introduction of a second carboxylic acid in
substrates 25 and 26 resulted in a considerable increase in
cleavage efficiency, with substrate 25 providing the highest
cleavage efficiency out of all the substrates tested. This result
is consistent with the known peptide substrate specificities for
many of the caspases, which prefer a second aspartic acid
residue at the P4 position, i.e., four amino acids away from the
cleavage site (Talanian et al., 1997).
SubstrateScreeningandOptimizationagainstCaspase-6
For peptide substrates, caspase-3 and -6 both require an
aspartic acid residue at the site of cleavage but differ in preferredElsevier Ltd All rights reserved
Figure 2. Caspase-3 Cleavage Efficiencies of AMCA Substrates
(A) Relative kcat/Km of initial substrate library incorporating alkyl and polar R groups. The relative kcat/Kmof the least efficiently cleaved substrate for which turnover
could be detected was assigned a value of 1.0. For caspase-3, substrate 2 was assigned a value of 1.0.
(B) Relative kcat/Km of substrate set incorporating a-substituted amide R structures.
(C) Relative kcat/Km of N-substituted amide substrates with (S)-configured methyl and cyclohexyl substituents.
See also Figure S1.
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the cleavage site (Thornberry et al., 1997). In P2, caspase-3
shows a strong preference for small hydrophobic residues,
whereas caspase-6 tolerates larger residues. In P4, caspase-3
demonstrates an almost absolute requirement for an aspartic
acid residue, whereas larger aliphatic residues are tolerated byChemistry & Biology 17, 1189–120caspase-6. Therefore, all of the previously synthesized cas-
pase-3 substrates were assayed against caspase-6 with key
substrate activity relationships represented by the substrates
shown in Figure 3A. No substrate turnover was observed
for a-monobranched substrates, as exemplified by substrates
10 and 13, therefore, they were given the relative cleavage0, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1191
Figure 3. Caspase-3 and -6 Cleavage Efficiencies of AMCA Substrates
(A) Relative kcat/Km of a select number of previously synthesized AMCA substrates against caspase-3 and -6. The relative kcat/Km of the least efficiently cleaved
substrate for which turnover could be detected was assigned a value of 1.0. For caspase-3, substrate 2 was assigned a value of 1.0 (Figure 2A). For caspase-6,
substrate 19 was assigned a value of 1.0.
(B) Relative kcat/Km of newly synthesized substituted phenylamide substrates against caspase-6.
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only substrates 18 and 19 with methyl and cyclohexyl substitu-
ents resulted in cleavage. Substrate 19 gave the lowest cleavage
efficiency out of all the substrates for which turnover was
detected for caspase-6 and was assigned a relative cleavage
efficiency of one. The (S)-epimer of substrate 18 provided
a 5-fold increase in cleavage efficiency relative to substrate 19,
consistent with the stereochemical preference observed for cas-
pase-3. For substrate 25, incorporating the carboxylic acid
functionality resulted in a greater than 2-fold increase in cleavage
efficiency, whereas no substrate turnover was detected for
substrate 26, which also contains the carboxylic functionality
but with a shorter chain length. The importance of the H-bond
accepting capability of the amide carbonyl is apparent by com-
paring the cleavage rate of amide substrate 21 and amine sub-
strate 22. The phenylacetamide substrate 23 provided a consid-
erable increase in cleavage efficiency, with the corresponding
isosteric phenylmethylsulfonamide substrate 24 also serving as
a good substrate but with 3-fold lower efficiency than 23.
Figure 3A displays notable differences in SARS between
caspase-3 and caspase-6 substrates. The chiral preference for
(S)-epimer 18 was stronger for caspase-3 over caspase-6. This
can be explained by the difference in size of the S2 pocket
between caspase-3 and caspase-6. Various substitutions are
tolerated in P2 for both caspases, but caspase-6 is able to
accommodate larger aliphatic and aromatic residues in contrast
to caspase-3. A difference in relative cleavage efficiencies
between benzamide 21 and phenylacetamide 23 was observed
for caspase-3 and caspase-6. Substrate 23 showed only a
modest increase in cleavage efficiency compared to substrate
21 for caspase-3, whereas 23 displayed a >18-fold increase
compared to 21 for caspase-6. Consistent with the known
peptidic substrate specificity data for caspase-3 and -6 (see1192 Chemistry & Biology 17, 1189–1200, November 24, 2010 ª2010above), substrate 25with an acidic side chain capable of binding
in the S4 pocket was the most efficiently cleaved by caspase-3;
whereas substrate 23 displaying hydrophobic functionality was
the most efficiently cleaved by caspase-6.
Because substrate 23 incorporating the phenylacetamide
showed by far the greatest cleavage efficiency by caspase-6,
analogs with substitution on the phenyl ring were prepared and
evaluated (Figure 3B). Methyl and phenyl electron-donating
substituents at the meta position in substrates 27 and 28
decreased cleavage efficiency. The considerably lower cleavage
efficiency of substrate 28 can be attributed to unfavorable steric
interactionswith the large phenyl substituent.Modest reductions
in cleavage efficiency were also observed for substrates with
meta-substitution, with the more strongly electron-donating
phenoxy and methoxy substituents, 29 and 30, respectively, as
well as with the electron-withdrawing trifluoromethyl substituent
(substrate 31). The electron-donating methoxy substituent at the
para position provided an 8-fold drop in cleavage efficiency
(substrate 32). A slight decrease in cleavage efficiency was
also observed for the electron-withdrawing chloro substituent
at both the para and ortho positions, present in substrates 33
and 34, respectively.
Inhibitor Synthesis and Screening
The final step in the SAS method is conversion of the most
active substrates to inhibitors. Substrate cleavage is only
observed when the amide carbonyl of theN-acyl aminocoumarin
is properly positioned in the enzyme active site, thus allowing for
the aminocoumarin group to be replaced by a mechanism-
based pharmacophore to produce reversible or irreversible
inhibitors. Pharmacophore selection was based upon a class
of peptidic pan-caspase inhibitors containing the 2,3,5,6-tetra-
fluorophenoxy ketone irreversible inhibitor pharmacophoreElsevier Ltd All rights reserved
Figure 4. Irreversible 2,4,5,6-Tetrafluoro-
phenoxymethyl Inhibitors
(A) Pan-caspase inhibitor incorporating a 2,4,5,6-
tetrafluorophenoxymethyl ketone pharmacophore
developed by Idun Pharmaceuticals.
(B) Inactivation rates of irreversible 2,4,5,6-tetra-
fluorophenoxymethyl inhibitors against caspases
1–3 and 5–9, cathepsins B, S, and V, and legu-
main. aAssays determining kinact/Ki (M
1s1)
were performed in duplicate with SD values
included. bCaspase-2 assays determining kinact/
Ki (M
1s1) were performed in duplicate with SD
values included. cNo inhibition after 15 min of pre-
incubation with various concentrations of inhibitor
of up to 400 mM. dVery weak inhibitory activity pre-
vented determination of kinact/Ki values, but IC50
values of 200–350 mM were obtained after
15 min of preincubation.
See also Figures S2–S4.
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inhibitor series have advanced the farthest in clinical develop-
ment (Linton et al., 2004, 2005). Indeed, inhibitor IDN-6556 (Fig-
ure 4A) was determined to be nontoxic in mouse models and
has entered Phase II clinical trials for the treatment of human
liver preservation injury (Baskin-Bey et al., 2007). The 2,3,5,6-tet-
rafluorophenoxyketone pharmacophore was incorporated into
three distinct substrates, 23–25, that showed good cleavage effi-
ciency by both caspase-3 and -6 to provide inhibitors 35–37 (see
Supplemental Experimental Procedures for inhibitor synthesis
and characterization). The inhibitory activity of these compounds
was then characterized against a full panel of caspases 1–3 and
6–9 (Figure 4B). All three inhibitors provided potent inhibition of
caspases 3 and 6, with kinact/Ki values of >20,000 M
1s1 for
each enzyme. Each of the inhibitors also provided potent
inhibition of caspases 1 and 7–9, as would be expected by theChemistry & Biology 17, 1189–1200, November 24, 2010 ªsimilar substrate specificities across
these enzymes. In contrast to the other
caspases, caspase-2 has an extended
binding pocket, and a P5 residue has
been shown to be critical for increased
cleavage efficiency (Schweizer et al.,
2003; Talanian et al., 1997). Due to this
extended binding requirement, it is not
surprising that for inhibitors 35–37 poor
inhibition of caspase-2 was observed
with kinact/Ki values of <33 M
1s1.
Recent studies have demonstrated
that incorporation of P1 aspartyl side
chain functionality in caspase inhibitors
does not necessarily afford selective cas-
pase inhibition. Aspartyl peptidyl fluoro-
methyl and chloromethyl ketones have
been reported to efficiently inhibit other
cysteine proteases such as cathepsin B,
S, and V as well as legumain (Rozman-
Pungercar et al., 2003). More recently,
aspartyl peptidic acyloxymethyl ketones
have been utilized as efficient cell-perme-able activity-based probes for legumain (Sexton et al., 2007).
Due to the aforementioned studies, all three inhibitors were
screened against multiple cathepsins and legumain to evaluate
cross-reactivity. Inhibitors 35–37 displayed no inhibition of
cathepsins B and V. Weak inhibition was observed for cathepsin
S, with kinact/Ki values of <1138M
1s1. Inhibition of legumain by
35 and 36was so poor (IC50 = 200–350 mM at 15 min preincuba-
tion) that kinact/Ki values could not be calculated, and for inhibitor
37 absolutely no inhibition of this enzyme could be detected.
Overall, the caspase-designed aryloxymethyl ketone irreversible
inhibitors showed little to no inhibition against legumain,
cathepsin B, S, and V.
Evaluating Inhibitors in HD Models
In vitro, Htt is preferentially cleaved at amino acid 552 by cas-
pase-2, 513 by caspase-3, and 586 by caspase-6 (Hermel2010 Elsevier Ltd All rights reserved 1193
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Caspase Inhibition in Huntington’s Diseaseet al., 2004; Wellington et al., 2000). Inhibitors 35–37 were each
evaluated for Htt proteolysis by caspase-2, -3, and -6 with neo-
epitope antibodies that recognize the specificHtt cleavage prod-
ucts using an in vitro assay. Figure 5 shows western blot analysis
of cellular lysates expressing full-length Htt23Q and Htt148Q
treated with caspase-2, -3, and -6 and the three inhibitors at
various concentrations using the neo-specific Htt antibodies.
Although minimal protection against cleavage of Htt by cas-
pase-2 was observed as expected (Figure 5A), inhibitors 35–37
each effectively blocked proteolysis by caspase-3 at amino
acid 513 at all of the tested concentrations (0.1, 1.0, and
10 mM) (Figure 5B). For full-length Htt treated with caspase-6,
all three inhibitors, 35–37, also showed complete protection
from cleavage at amino acid 586 at concentrations of 1.0 and
10 mM (Figure 5C). To gain insight into the efficiency of the inhib-
itors for blocking caspase cleavage of Htt, we determined the
kcat/Km of full-length Htt with caspase-3 and caspase-6 (Table
S1), and it appears that Htt in lysates is less efficiently cleaved
by caspase-6 than caspase-3. This may correlate with the higher
dose required to inhibit caspase-6 cleavage of Htt; however,
without determining Km of Htt, we cannot compare the efficiency
of the inhibitors for the caspases.
Next, each inhibitor was evaluated in a HD cellular toxicity
model by measuring caspase activity and Htt proteolysis.
Because HD primarily affects striatal and cortical neurons, we
used immortalizedmouse striatal cellHdh7Q/7Q andHdh111Q/111Q
lines tomeasure cellular toxicity and Htt proteolysis (Trettel et al.,
2000). We cultured Hdh7Q/7Q and Hdh111Q/111Q cells and evalu-
ated Htt proteolysis 24 hr after serum withdrawal. We found
that the neoHtt513 antibody detected proteolysis of Htt in cells
and lysates (Figures 6A and 6B). Qualitatively, the levels of Htt
proteolysis are higher in the Hdh111Q/111Q when compared to
Hdh7Q/7Q lines (Figure 6B). Caspases are known to cleave the
Htt protein containing the polyglutamine expansion, and evi-
dence suggests that these N-terminal cleavage products lead
to cellular toxicity and apoptosis (Wellington et al., 1998). During
serumwithdrawal, we found thatHdh111Q/111Q cells have a 7-fold
increase in caspase activation compared to control Hdh7Q/7Q.
Cell death occurred at 48 hr after serum withdrawal (Figure S5).
All three irreversible inhibitors, 35–37, at concentrations of
1–100 mM were evaluated in Hdh7Q/7Q and Hdh111Q/111Q cells
and were found to significantly block caspase activity in both
the normal and expanded Htt cell model 24 hr after serum depri-
vation (Figure 6C). Furthermore, the irreversible inhibitors 35
and 37 at concentrations of 10–100 mM blocked the proteolysis
of Htt as detected by neoHtt513 (Figure 6D). Interestingly, inhib-
itor 36, which incorporates additional acidic carboxylic acid
functionality and thus has distinct physicochemical properties
relative to inhibitors 35 and 37, showed minimal effect. To deter-
mine the IC50 values for inhibitors 35–37, DEVDase activity was
measured as a function of concentration for each inhibitor (Fig-Figure 5. Inhibitors 35–37 Block Caspase-6 or Caspase-3 Mediated C
Full-length c-myc-Htt23Q and c-myc-Htt148Q were transiently transfected in HEK
caspase-2, -3, or -6 and inhibitors were probed with the indicated neo-specific a
cific band. The lysates contain endogenous wild-type Htt so this is also detected
less effective on caspase-2 cleavage of Htt. Because these are cellular lysates,
members yielding a slight effect on full-length Htt.
See also Table S1.
Chemistry & Biology 17, 1189–120ure 6E). Of note, the concentration needed to block caspase
activity was lower in the HD cells compared to WT. Perhaps
doses of caspase inhibitors can be utilized in therapeutics
that do not impact normal cellular function. We do not know
the exact mechanism for the lower dose required to inhibit the
caspases in the Hdh111Q/111Q cells, but two possible explana-
tions are: (1) the Hdh7Q/7Q caspase-3 activity is from the proform
of the enzyme that has a distinct kcat and Km when compared to
active caspase-3 (Hdh111Q/111Q could have more); or (2) the
endogenous inhibitors of caspases are lower in the HD cells
due to activation of degradative pathways such as proteasome
or autophagy.
Next, we evaluated these inhibitors ex vivo, using primary
co-cultures of striatal and cortical neurons expressing normal
and expanded Htt N-terminal fragments-Htt N90Q73, which
induces degeneration of rat striatal and cortical neurons in
primary co-cultures. We use co-cultures because in HD it is
known that non-cell autonomous interactions and deficits in
cortico-striatal circuitry occur. We use a fragment HD model
because we have found that these toxic Htt fragments cause
the activation of the same proteases involved in cleaving full-
length Htt and producing neurotoxicity. The percentage of
healthy striatal and cortical neurons after treatment with varied
concentrations of the irreversible inhibitors is shown in Figure 7
(see Figure S6 for relative reversibility of neuronal effects upon
removing irreversible inhibitors). All three inhibitors rescued stria-
tal neurons from cell death, and treatment with inhibitor 35 re-
sulted in the most significant increase of healthy striatal neurons
at 0.4, 1.2, and 3.7 nM. The same trend is observed for the treat-
ment of cortical neurons, with 35 resulting in a substantial
increase (25%–175%) in healthy neurons. The control is trans-
fection of the fluorescent protein-encoding plasmid and empty
plasmid in place of Htt plasmid. For the striatal the control is
237% ± 25%. For the cortical, the control is 311% ± 60%. This
suggests that some doses of the inhibitors completely rescued
the cell death mediated by mutant Htt. The efficacy of the inhib-
itors at even single-digit nanomolar concentrations is likely due
to the greater sensitivity of primary cultures to cell death when
compared to the immortalized cells. Primary cultures are termi-
nally differentiated, and the culture conditions are distinct
when compared to the immortalized mouse striatal Hdh7Q/7Q
and Hdh111Q/111Q cell system.
Conclusions
The SASmethodwas applied to caspase-3 and -6, leading to the
identification of 1,2,3-triazole-based nonpeptidic substrates
with high cleavage efficiencies. Subsequent replacement of the
aminocoumarin reporter group with the 2,3,5,6-tetrafluorophe-
noxymethyl ketone pharmacophore in the most efficient
substrates led to three novel nonpeptidic irreversible inhibitors
showing strong potency against caspases and weak to noleavage of Htt
293T cells for 72 hr. Western blots of cellular lysates treated with recombinant
ntibody recognizing the Htt cleavage fragment. The asterisk indicates nonspe-
in the right panel in (A) and (B). For (C) it should be noted that the inhibitors are
it is possible that addition of caspase-2 activates some of the other caspase
0, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1195
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Figure 7. Protective Effects of Caspase Inhibitors in HttN90Q73-
Induced Degeneration of Rat Striatal and Cortical Neurons in
Primary Co-Culture
Rat striatal and cortical neurons expressing HttN90Q73 together with YFP or
mCherry, respectively, combined in primary co-culture and treated with
DMSO or caspase inhibitors at the indicated doses. YFP-positive striatal
neurons and mCherry-positive cortical neurons were quantified at 6 days after
transfection by automated fluorescent object detection on the Cellomics
ArrayScan VTI. All conditions were normalized against the DMSO condition
set to 100%. N = 6 for each condition; error bars are standard deviation. Aster-
isks indicate significant difference from the DMSO condition using one-way
ANOVA followed by Dunnett post hoc comparison. Analysis indicates the
statistical significance as: *p < 0.05.
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Caspase Inhibition in Huntington’s Diseaseinhibition of other cysteine proteases previously reported to have
cross reactivity with published caspase inhibitors. All three inhib-
itors, 35–37, blocked proteolysis of Htt at the caspase-3 and -6
cleavage sites, amino acids 513 and 586, respectively. More-Figure 6. Inhibitors 35–37 Block Caspase Activation in Mouse Striatal
(A) StriatalHdh7Q/7Q andHdh111Q/111Q cells were cultured for 48 hr and then subjec
Hdh111Q/111Q cells with neoHtt513 demonstrates cleavage of Htt. Qualitatively, m
(B) Western blot analysis using neoHtt513 antibody demonstrates proteolysis o
withdrawal.
(C) Striatal Hdh7Q/7Q and Hdh111Q/111Q cells where cultured for 48 hr and then ca
have a 7-fold increase in caspase activation compared to control Hdh7Q/7Q. Inhib
were repeated three times, each time with an n = 3. ANOVA analysis indicates th
(D) Striatal Hdh7Q/7Q and Hdh111Q/111Q cells were cultured for 48 hr. Then, 24 hr a
proteolysis of Htt at the caspase-3 cleavage site located at amino acid 513 at th
See also Figures S5 and S6.
Chemistry & Biology 17, 1189–120over, in a HD model, all three inhibitors rescued cell death in
striatal and cortical neurons at nanomolar concentrations. These
pan-caspase inhibitors continue to be applied as tool
compounds in studies of Htt proteolysis and toxicity. Future
work will be directed at evaluating these compounds in mouse
models of HD to determine their effect on the pathogenesis of
HD.SIGNIFICANCE
HD is an incurable disease caused by a mutation encoding
a polyglutamine expansion in the N terminus of the hunting-
tin protein. Major research efforts have focused on the rela-
tionship of polyglutamine repeats and HD pathogenesis.
Proposed mechanisms leading to neuronal dysfunction
and death include formation of polyglutamine aggregates
and inclusions (Arrasate et al., 2004; Sawada et al., 2007),
altered confirmation of mutant huntingtin leading to tran-
scriptional dysregulation (Dunah et al., 2002; Li et al., 2002;
Zhai et al., 2005), excitotoxic neuron damage by excessive
stimulation of glutamate receptors (Charvin et al., 2008;
Fan et al., 2007; Stack et al., 2007), and induction of
apoptosis and proteolysis. Evidence has emerged that
suggest Htt fragments lead to neuronal toxicity, but the
exact mechanism remains unknown. The proteolytic
cleavage of Htt and the enzymes involved in this process
have emerged as potential therapeutic targets for treating
HD.
Caspases are proteases involved in programmed cell
death and have been found to cleave Htt. Specifically, accu-
mulation of caspase-cleaved Htt fragments represents a
neuropathological hallmark of HD. Furthermore, Graham
et al. (2006) showed that mice expressing mutant Htt resis-
tant to cleavage by caspase-6, and not caspase-3, exhibit
normal neuronal function and do not develop neurodegener-
ation. Therefore, inhibitors that block caspase cleavage
provide a promising starting point for the study of Htt
proteolysis.
A substrate-based fragment approach was used to
develop three nonpeptidic irreversible inhibitors displaying
pan-caspase activity. In vitro, these inhibitors blocked Htt
cleavage by caspase-3 and -6. Results from a HD cellular
toxicity model showed that all three inhibitors dramatically
blocked caspase activation in disease model cells. Ex vivo
studies using cultures of striatal and cortical neurons ex-
pressing mutant Htt demonstrated the rescue of neuronal
death after treatment with the inhibitors. Overall, theHdh7Q/7Q and Hdh111Q/111Q Cells
ted to analysis 24 hr after serumwithdrawal. Immunochemistry ofHdh7Q/7Q and
ore Htt cleavage is found in the Hdh111Q/111Q cells.
f Htt at the caspase-3 cleavage site located at amino acid 513 after serum
spase activity was measured 24 hr after serum withdrawal. Hdh111Q/111Q cells
itors 35–37 blocked caspase activity at the doses indicated. The experiments
e statistical significance: *p < 0.05, **p < 0.01, and ***p < 0.005.
fter serum withdrawal cell lysates were prepared. Inhibitors 35–37 blocked the
e indicated doses.
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blocking caspase Htt cleavage and rescue of HD-mediated
neurodegeneration.
EXPERIMENTAL PROCEDURES
Fluorogenic Substrate Screen against Caspase-3 and -6
Caspase-3 and -6–9 were obtained by expression in E. coli as previously
described (Stennicke and Salvesen, 1999). Caspase-1, cathepsin B, L, and
V were purchased from EMD Biosciences (San Diego, CA, USA), caspase-2
was purchased from Biomol International (Plymouth Meeting, PA, USA), and
Legumain was purchased from R&D Systems (Minneapolis, MN, USA). Assays
were conducted at 37C in duplicate with and without the enzyme in Dynatech
Microfluor fluorescence 96 well microtiter plates, and readings were taken on
a Molecular Devices Spectra Max Gemini XS instrument according to previ-
ously reported protocols (see Supplemental Experimental Procedures for full
assay details for each enzyme). Caspases 3 and 6were used at concentrations
2.7 and 3.0 mM, respectively. Relative fluorescent units (RFU) were measured
at regular intervals over a period of time (maximum 15 min). A plot of RFU
versus time was made for each substrate with and without enzyme. The slope
of the plotted line gave relative kcat/Km of each substrate.
Inhibitor Kinetic Assays
Caspase substrates Ac-DEVD-AMC (caspases 3 and 6–8), Ac-VDVAD-AFC
(caspase-2), and Ac-LEHD-AFC (caspase-9) were purchased from EMD
Biosciences, and Ac-VDVAD-AMC (caspase-2) was purchased from Biomol
International. Cathepsins B and V substrate Cbz-FR-AMC was purchased
from EMD Biosciences. Cathepsin S substrate Cbz-LR-AMC and legumain
substrate Cbz-AAN-AMC were purchased from Bachem (Torrance, CA,
USA). Assay wells contained a mixture of inhibitor and substrate in buffer
(see Supplemental Experimental Procedures for full assay details for each
enzyme). Aliquots of enzyme were added to each well to initiate the assay.
Hydrolysis of the fluorescent substrate was monitored fluorometrically for
45 min. The kinact/Ki for inhibitors was determined under pseudo-first order
conditions using the progress curve method (Bieth, 1995; Ekici et al., 2006).
Inhibition was measured in triplicate, and the average and standard deviation
is reported. Detailed procedures for each enzyme, including buffer conditions
and enzyme, inhibitor and substrate concentrations, are provided in the first
Supplemental Experimental Procedures.
Htt Neoepitope Antibody Production
Antibodies specific for the C-terminal ends of Htt caspase cleavage products
ending at amino acid 513, 552, and 586 were prepared using the immuniz-
ing peptides KLH-DHTLQADSVD, KLH-DSDPAMDLND, and KLH-COSDS-
SEIVLD. Peptide sequences were injected into rabbits, antibody was purified
to the injected peptide, and a bridging peptide was used to remove antibodies
reacting to full-length Htt (Open Biosystems). Antibodies were affinity purified
as previously described with minor modifications (Wellington et al., 2002;
Gervais et al., 1999).
Htt Constructs
Htt expression constructs used in these studies included a normal (23Q) and
expanded (148Q) full-length Htt construct.
Cell Culture
SuperFect reagent (QIAGEN) was used for transient transfections of human
embryonic kidney (HEK) 293T cells with Htt constructs. Cells were collected
60 hr after transfection for analysis. 293T cells or striatal Hdh7Q/7Q and
Hdh111Q/111Q cells were cultured in Dulbecco’s modified eagle medium
(DMEM; Cellgro) with 10% fetal bovine serum (FBS) and 100 U/ml penicillin
and 100 mg/ml streptomycin.
Western Analysis
293T cell pellets were lysed inM-PER (Mammalian Protein Extraction Reagent,
Pierce) with protease inhibitors (Mini Complete, Roche), lysates were soni-
cated and then spun to remove debris (16,000 3 g, 20 min). Protein concen-
tration was determined by a BCA Protein Assay kit (Pierce). Htt-expressing1198 Chemistry & Biology 17, 1189–1200, November 24, 2010 ª2010lysates were in some cases treated exogenously with caspases 2, 3, or 6
(ENZO, 100 U, 2 hr, 37C) with and without inhibitors 35–37. Samples were
resolved by SDS-PAGE on NuPAGE 4–12% BisTris gel (Invitrogen) in MES
running buffer (Invitrogen) for 55 min at 200 V. Proteins were transferred to
Optitran BA-S nitrocellulose (Schleicher & Schuell) for 14 hr at 20 V at 4C.
Membranes were blocked in 5% milk in Tris-buffered saline Tween-20 and
probed overnight at 4Cwith polyclonal neoHtt513, neoHtt552, and neoHtt586
(Open Biosystems; 1:1000 or 1:100, produced in collaboration with CHDI/
Open Biosystems) or monoclonal a-Huntingtin 2166 (Chemicon; 1:1000).
Secondary anti-rabbit or anti-mouse antibodies (1:3000; Amersham Biosci-
ences/GE Healthcare) and enhanced chemiluminescence (ECL) reagent
(Pierce) were used for detection. We utilized anti-GAPDH as the loading
control (Fitzgerald No. 10R-G109a; 1:1000).
kcat/Km of Htt with Caspases
293T cells overexpressingmyc-tagged 23Q human full-lengthHtt were lysed in
M-PER (Mammalian Protein Extraction Reagent, Pierce), sonicated and spun
to remove debris (16,000 3 g, 20 min). Protein was determined using a BCA
assay kit (Pierce). Purified human poly-(ADP-ribose) polymerase (PARP) was
obtained from Trevigen (Gaithersburg, MD, USA). Htt lysate (15 mg) was incu-
bated with caspase-3 (4 nM; ENZO) or caspase-6 (48 nM; ENZO) for 60 min
at 37C in caspase assay buffer (20 mM PIPES [pH 7.2], 100 mM NaCl, 1%
CHAPS, 10% sucrose). Purified PARP (35 ng) was incubated with caspase-3
(7.2–144 nM) under identical conditions. NuPAGE LDS sample buffer (Invitro-
gen) and 50 mM DTT were added, and samples were boiled and separated
using SDS-PAGE. Following transfer to nitrocellulose membranes, Htt protein
blots were incubated in monoclonal Htt 2166 (1:500; Millipore), PARP protein
blots were incubated in polyclonal PARP 253 (1:300; ENZO), and densitometry
of bands was performed. All reactions were carried out using subsaturating
levels of substrate, where the cleavage is assumed to be a first-order process.
Values of kcat/Km were calculated from the relationship St/So = e
kobs*t, where
St=concentration of substrate remainingat time t,So= initial substrate concen-
tration, and kobs = kcat*[enzyme]/Km (Gervais et al., 1998).
Caspase Activity in Striatal Hdh7Q/7Q and Hdh111Q/111Q Cells
Striatal Hdh7Q/7Q and Hdh111Q/111Q cells were maintained at 33C in a humidi-
fied atmosphere of 95% air and 5% CO2, in DMEM supplemented with 10%
FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin. Cells were fedwith fresh
media every 2–3 d. Striatal cells were plated at 5000 cells/well in collagen-
coated 96well plates andwere grown for 48 hr. Cells weremaintained in serum
DMEM for 24 hr with or without caspase inhibitors and an additional 24 hr
without serum with same inhibitor treatment. Caspase 3/7 activity was
measured using the APO3 HTS kit per manufacturer’s direction (Mountain
View, CA, USA) and normalized by protein concentration. Briefly, cells were
lysed in working cell lysis buffer (50 ml, 1:1 lysis buffer: serum-free DMEM)
by shaking at 700 rpm for 5 min, and a 20 ml aliquot was measured for protein
concentration. Afterward, 70 ml of working lysis buffer with DTT (15 mM), and
caspase substrate (13) was added to remaining lysed cells, shaken briefly,
and read continuously at 37C for 90 min with excitation at 488 nm and emis-
sion at 530 nm.
Immunocytochemistry
Striatal Hdh7Q/7Q and Hdh111Q/111Q cells cultured on coverslips with or without
serum withdrawal were fixed with 4% paraformaldehyde for 20 min at room
temperature. The fixed cells were then permeabilized with 0.1% Triton
X-100 for 10 min and blocked with 5% donkey serum for 45 min. The incuba-
tion with the primary antibody (rabbit polyclonal neoHtt513, 1:100) at 4Cover-
night was followed by secondary antibody (donkey anti rabbit Alexa546,
1:1000; Invitrogen) incubation at room temperature for 1.5 hr. Finally, cells
were mounted to a slide with droplets of Prolong Gold with DAPI (Invitrogen)
on it before microscopy.
Primary Cortico-Striatal Co-Culture
Striatum and cortex from E18 rat embryos weremicrodissected, enzymatically
treated with papain, and dissociated. Five million cells of each type were elec-
troporated separately (Amaxa Biosystems) with DNA constructs expressing
either YFP in striatal neurons or mCherry in cortical neurons together with
a plasmid expressing mutant polyQ expanded Htt exon1 (HttN90Q73), thenElsevier Ltd All rights reserved
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method for assessing culture health in experiments is by determining the
number and morphology of GFP-expressing cells. In developing the assay
we found with vital stains that about 50% of cells die immediately after the
electroporation. The neurons that survive the electroporation appear to be
healthy, extending neurites and forming functional synapses, as assessed
by synaptic marker staining and electrophysiology (Kaltenbach et al., 2010).
Neurons and astrocytes were grown in Neurobasal media (Invitrogen) supple-
mented with 5% fetal calf serum (Sigma), 2 mM glutamine (GlutaMAX; Invitro-
gen), 10 mM potassium chloride, and 5 mg/ml gentamycin. Astrocytes were
isolated from E18 embryos and expanded for three passages before plating
into 96 well plates. Co-cultures were incubated in 95% O2/5% CO2 at 37
C
for 6 days before analysis. Compounds were dissolved in DMSO and dosed
as a single dose shortly after neuron plating. The control condition was
HttN90Q73 with DMSO alone. For quantification of neurons using the Cello-
mics ArrayScan VTI, fluorescent images were acquired at 103 magnification
from nine fields per well using YFP and dsRED filter sets and analyzed using
the Target Activation algorithm. The algorithm was optimized for object size,
object shape, and fluorescence intensity to identify specific neuron cell bodies.
Healthy neurons are easily identified by the size of the cell body and neuritic
morphology. Graphical analysis and statistical computations were performed
with GraphPad Prism.
SUPPLEMENTAL INFORMATION
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